Clin2
NCT07587684Possibly a fitRecruiting

Testing IN026 for Hard-to-Treat Gout

Refractory Gout

Part of Bones, joints & muscles, Genetic & congenital, Hormones & metabolism, Skin clinical trials.

This study tests a new drug called IN026 for people with refractory gout—gout that doesn't respond well to current treatments and causes severe symptoms. The goal is to see if IN026 can lower uric acid levels and reduce gout attacks.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
16 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You must have gout that is difficult to control (high uric acid levels and severe symptoms despite treatment)
  • Your gout must be confirmed by 2015 ACR/EULAR criteria, and you must not be having an active gout attack (or it must have resolved at least 2 weeks ago)
  • Your serum uric acid level must be at least 420 μmol/L (7 mg/dL) at screening
  • You must be between 18 and 75 years old
  • You cannot have certain infections (hepatitis B, hepatitis C without successful treatment, HIV, or active syphilis)
  • You must not have taken other urate-lowering drugs, uricase agents, or certain vaccines in the required timeframe before enrollment

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06653686Not yet recruiting
Heat therapy for hard-to-treat gout

This trial tests if heat therapy can help people with gout that doesn't get better with standard treatments. It aims to reduce flare-ups and improve symptoms.

NCT07145229Recruiting· Phase 2
Testing a new drug for acute gout flares

This trial tests a new medication, ABP-745, for people having an acute gout flare. It aims to see if the drug is safe and helps reduce pain and inflammation.

Peoria, Arizona
NCT06629376Recruiting· Phase 1
Testing a new gout drug for safety and effect on uric acid

This trial tests an experimental drug, SSS11, to see if it is safe and how it affects uric acid levels in people with gout and high uric acid. You may not take other gout medicines during the study.

Shanghai
NCT07708181Not yet recruiting· Phase 2
SSGJ-613 injection for gout flare prevention

This trial tests an injection called SSGJ-613 to see if it can prevent gout flares in people who are starting a medication to lower uric acid. It's for people with frequent gout attacks.

NCT07498647Not yet recruiting· Phase 2
Testing a new gout medicine for people with high uric acid

This trial tests a new tablet called BR2251 for people with gout and high uric acid. It aims to lower uric acid levels and manage gout symptoms.

NCT07280156Recruiting· Phase 2
Study of PRX-115 for gout with or without methotrexate

This trial tests a new medicine, PRX-115, given through a vein, to see if it lowers uric acid levels in people with gout who haven't had success with standard treatments. Some participants will also take methotrexate, and the results are compared to a placebo (a dummy infusion).

Little Rock, Arkansas

Hear when a new Refractory Gout trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.